TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

ABSTRACT: This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response. This trial will study the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TTX-030 in combination with immunotherapy and/or standard chemotherapies.

DISEASE(S): Non-small Cell Lung Cancer,Colorectal Cancer,Advanced Solid Tumor,Bladder Cancer,Solid Tumor, Adult,Pancreatic Cancer,Neoplasms,Cancer

PROVIDER: 2332975 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR